Targeted therapy in cancer treatment focused on specific genes or proteins found in cancer cells that make them different from other normal cells. This is different from chemotherapy, which often kills all cells that grow and divide quickly. Those specific genes or proteins are often involved in controlling the growth, progression, and metastasis of cancer cells. It is the foundation of precision medicine. Most targeted therapies are either small-molecule drugs or monoclonal antibodies. However, targeted therapy does have some drawbacks.
Accumulating evidence from research and clinics has suggested that cancer cells can become resistant to targeted therapy, resulting in treatment failure. Resistance can happen when the target itself changes and the targeted therapy is not able to interact with it. Or it can happen when cancer cells find new ways to grow that do not depend on the target. Because of resistance, the development of novel drug and treatment strategies is needed to conquer drug resistance to targeted therapy.
Accumulating evidence has suggested that cancer cells may develop cross-resistance to various structurally and functionally unrelated chemotherapeutic agents, resulting in treatment failure. This phenomenon is known as multi-drug resistance. This article collection will also welcome submissions that look at new targets and insights into the issue associated with drug resistance when developing target-ed therapy.
The main goals we would like to see addressed in this Research Topic include:
• To explore novel mechanistic insights on molecular pathways and/or cellular processes involved in targeted therapy.
• To identify new targets for future potential therapeutic approaches and/or development of new technology.
• To illustrate new insights on drug resistance to targeted therapy.
• To provide directions for treatment strategies in clinical settings and improve the quality of cancer patient’s life.
• To serve as a valuable indication for follow-up clinical investigations in monitoring molecular targets or the use of therapeutic agents.
This Research Topic welcomes submissions of Original Research and Review articles within the scope of cancer-targeting agents including hormone therapies, signal transduction inhibitors, apoptosis inducers, angiogenesis inhibitors, immunotherapies, monoclonal antibodies, etc. Some examples of potential sub-topics include, but are not limited to:
• Identification and analysis of novel mechanisms of action involved in targeted therapy against cancer.
• Research into new signalling pathways involved in targeted therapy against cancer.
• New therapeutic targets or approaches for targeted therapy.
• New targets and new insights on resistance issues associated with these targeted drugs.
• Crosstalk or interaction between drug resistance and targeted therapy.
• Clinical insights in the context of research on targeted therapy.
• Approaches that can improve prognosis and the quality of cancer patient’s life during targeted cancer treatment.
Targeted therapy in cancer treatment focused on specific genes or proteins found in cancer cells that make them different from other normal cells. This is different from chemotherapy, which often kills all cells that grow and divide quickly. Those specific genes or proteins are often involved in controlling the growth, progression, and metastasis of cancer cells. It is the foundation of precision medicine. Most targeted therapies are either small-molecule drugs or monoclonal antibodies. However, targeted therapy does have some drawbacks.
Accumulating evidence from research and clinics has suggested that cancer cells can become resistant to targeted therapy, resulting in treatment failure. Resistance can happen when the target itself changes and the targeted therapy is not able to interact with it. Or it can happen when cancer cells find new ways to grow that do not depend on the target. Because of resistance, the development of novel drug and treatment strategies is needed to conquer drug resistance to targeted therapy.
Accumulating evidence has suggested that cancer cells may develop cross-resistance to various structurally and functionally unrelated chemotherapeutic agents, resulting in treatment failure. This phenomenon is known as multi-drug resistance. This article collection will also welcome submissions that look at new targets and insights into the issue associated with drug resistance when developing target-ed therapy.
The main goals we would like to see addressed in this Research Topic include:
• To explore novel mechanistic insights on molecular pathways and/or cellular processes involved in targeted therapy.
• To identify new targets for future potential therapeutic approaches and/or development of new technology.
• To illustrate new insights on drug resistance to targeted therapy.
• To provide directions for treatment strategies in clinical settings and improve the quality of cancer patient’s life.
• To serve as a valuable indication for follow-up clinical investigations in monitoring molecular targets or the use of therapeutic agents.
This Research Topic welcomes submissions of Original Research and Review articles within the scope of cancer-targeting agents including hormone therapies, signal transduction inhibitors, apoptosis inducers, angiogenesis inhibitors, immunotherapies, monoclonal antibodies, etc. Some examples of potential sub-topics include, but are not limited to:
• Identification and analysis of novel mechanisms of action involved in targeted therapy against cancer.
• Research into new signalling pathways involved in targeted therapy against cancer.
• New therapeutic targets or approaches for targeted therapy.
• New targets and new insights on resistance issues associated with these targeted drugs.
• Crosstalk or interaction between drug resistance and targeted therapy.
• Clinical insights in the context of research on targeted therapy.
• Approaches that can improve prognosis and the quality of cancer patient’s life during targeted cancer treatment.
